# Dexcom Inc: overview

DXCM · Nasdaq · CIK 1093557 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dxcm.md) · [Financials](/companies/dxcm/financials.md) · [Filings](/companies/dxcm/filings.md) · [Insiders](/companies/dxcm/insiders.md)

Latest reported revenue: [$1.31bn](/filings/0001093557-26-000143.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001093557-26-000143).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [994](/filings/0001093557-25-000280.md) | [1,114 d](/filings/0001093557-26-000027.md) | [1,036](/filings/0001093557-26-000073.md) | [1,157](/filings/0001093557-26-000143.md) | [1,209](/filings/0001093557-25-000280.md) | [1,260 d](/filings/0001093557-26-000027.md) | [1,192](/filings/0001093557-26-000073.md) | [1,308](/filings/0001093557-26-000143.md) |
| Gross margin | % | [59.7%](/filings/0001093557-25-000280.md) | [58.9% d](/filings/0001093557-26-000027.md) | [56.9%](/filings/0001093557-26-000073.md) | [59.5%](/filings/0001093557-26-000143.md) | [60.5%](/filings/0001093557-25-000280.md) | [62.9% d](/filings/0001093557-26-000027.md) | [62.9%](/filings/0001093557-26-000073.md) | [63.4%](/filings/0001093557-26-000143.md) |
| Operating margin | % | [15.3%](/filings/0001093557-25-000280.md) | [17.0% d](/filings/0001093557-26-000027.md) | [12.9%](/filings/0001093557-26-000073.md) | [18.4%](/filings/0001093557-26-000143.md) | [20.1%](/filings/0001093557-25-000280.md) | [25.6% d](/filings/0001093557-26-000027.md) | [21.4%](/filings/0001093557-26-000073.md) | [24.3%](/filings/0001093557-26-000143.md) |
| Net margin | % | [13.5%](/filings/0001093557-25-000280.md) | [13.6% d](/filings/0001093557-26-000027.md) | [10.2%](/filings/0001093557-26-000073.md) | [15.5%](/filings/0001093557-26-000143.md) | [23.5%](/filings/0001093557-25-000280.md) | [21.2% d](/filings/0001093557-26-000027.md) | [16.7%](/filings/0001093557-26-000073.md) | [19.0%](/filings/0001093557-26-000143.md) |
| Diluted EPS | $ per share | [0.34](/filings/0001093557-25-000280.md) | not reported | [0.27](/filings/0001093557-26-000073.md) | [0.45](/filings/0001093557-26-000143.md) | [0.70](/filings/0001093557-25-000280.md) | not reported | [0.51](/filings/0001093557-26-000073.md) | [0.64](/filings/0001093557-26-000143.md) |
| Free cash flow | $m | [88.3 d](/filings/0001093557-25-000280.md) | [177 d](/filings/0001093557-26-000027.md) | [96.8](/filings/0001093557-26-000073.md) | [209 d](/filings/0001093557-26-000143.md) | [579 d](/filings/0001093557-25-000280.md) | [192 d](/filings/0001093557-26-000027.md) | [449](/filings/0001093557-26-000073.md) | [185 d](/filings/0001093557-26-000143.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,449](/filings/0001093557-24-000021.md) | [2,910](/filings/0001093557-25-000036.md) | [3,622](/filings/0001093557-26-000027.md) | [4,033](/filings/0001093557-26-000027.md) | [4,662](/filings/0001093557-26-000027.md) |
| Gross margin | % | [68.6%](/filings/0001093557-24-000021.md) | [64.7%](/filings/0001093557-25-000036.md) | [63.2%](/filings/0001093557-26-000027.md) | [60.5%](/filings/0001093557-26-000027.md) | [60.1%](/filings/0001093557-26-000027.md) |
| Operating margin | % | [10.9%](/filings/0001093557-24-000021.md) | [13.4%](/filings/0001093557-25-000036.md) | [16.5%](/filings/0001093557-26-000027.md) | [14.9%](/filings/0001093557-26-000027.md) | [19.6%](/filings/0001093557-26-000027.md) |
| Net margin | % | [8.9%](/filings/0001093557-24-000021.md) | [11.7%](/filings/0001093557-25-000036.md) | [14.9%](/filings/0001093557-26-000027.md) | [14.3%](/filings/0001093557-26-000027.md) | [17.9%](/filings/0001093557-26-000027.md) |
| Diluted EPS | $ per share | [0.53](/filings/0001093557-24-000021.md) | [0.82](/filings/0001093557-25-000036.md) | [1.30](/filings/0001093557-26-000027.md) | [1.42](/filings/0001093557-26-000027.md) | [2.09](/filings/0001093557-26-000027.md) |
| Free cash flow | $m | [53.3](/filings/0001093557-24-000021.md) | [305](/filings/0001093557-25-000036.md) | [512](/filings/0001093557-26-000027.md) | [631](/filings/0001093557-26-000027.md) | [1,077](/filings/0001093557-26-000027.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dxcm/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-27 | [Stern Sadie](/insiders/1797971.md) | EVP Chief People & Culture Off, Officer | Sale (S) | 2,565 | $78.62 | $201.7k | [Form 4](/filings/0001093557-26-000187.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.58bn | 38,244,137 |  | Reduced −720,234 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.70bn | 25,209,752 |  | Added +188,791 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.32bn | 19,656,540 |  | Added +436,587 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.24bn | 18,380,806 |  | Added +445,959 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $1.03bn | 15,288,133 |  | Added +9,693,273 |
| [BAILLIE GIFFORD & CO](/funds/1088875.md) | 2026-06-30 | $996.9m | 14,801,590 |  | Reduced −797,935 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $834.2m | 12,426,515 |  | Added +79,877 |
| [UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC](/funds/861177.md) | 2026-06-30 | $758.5m | 11,261,876 |  | Added +1,515,702 |
| [ALLIANCEBERNSTEIN L.P.](/funds/1109448.md) | 2026-06-30 | $734.3m | 11,693,409 |  | Reduced −1,230,235 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $574.3m | 8,527,471 |  | Reduced −798,769 |

## Recent filings

[All 2,232 filings](/companies/dxcm/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:03 ET | [8-K](/filings/0001093557-26-000193.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001093557-26-000193 |
| 2026-09-14 | 16:33 ET | [8-K](/filings/0001093557-26-000175.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001093557-26-000175 |
| 2026-09-10 | 16:16 ET | [8-K](/filings/0001093557-26-000167.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001093557-26-000167 |
| 2026-07-30 | 17:21 ET | [10-Q](/filings/0001093557-26-000143.md) | Quarterly report, period 2026-06-30 | 0001093557-26-000143 |
| 2026-07-30 | 16:03 ET | [8-K](/filings/0001093557-26-000142.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001093557-26-000142 |
| 2026-05-28 | 17:15 ET | [8-K](/filings/0001093557-26-000105.md) | 5.07 Shareholder vote results | 0001093557-26-000105 |
| 2026-05-15 | 19:31 ET | [8-K](/filings/0001093557-26-000085.md) | 7.01 Regulation FD disclosure; 8.01 Other events | 0001093557-26-000085 |
| 2026-04-30 | 17:20 ET | [10-Q](/filings/0001093557-26-000073.md) | Quarterly report, period 2026-03-31 | 0001093557-26-000073 |
| 2026-04-30 | 16:02 ET | [8-K](/filings/0001093557-26-000072.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001093557-26-000072 |
| 2026-04-15 | 16:11 ET | [DEF 14A](/filings/0001093557-26-000061.md) | Proxy statement, period 2026-05-27 | 0001093557-26-000061 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001093557-26-000027.md), filed Feb 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/c6560137-3c5e-424c-9154-d280c4c5ab6d)

## About the filer

- CIK: 1093557
- Tickers: DXCM
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:23 ET. No prices; not investment advice.